The study will evaluate the efficacy of AZD5423 in patients with mild asthma challenged with an inhaled allergen - Allergen

Study identifier:D2340C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A double-blind, double-dummy, randomised, placebo-controlled, 4-way, crossover, multi-centre Phase II study with budesonide as an active control to evaluate the efficacy and safety of 2 doses of inhaled AZD5423 over 7 days in patients with mild allergic asthma challenged with an inhaled allergen

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD5423, AZD5423, AZD5423, AZD5423, Budesonide 200 microgram, Budesonide 200 microgram, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo, Placebo

Sex

All

Actual enrollment

27

Study type

Interventional

Age

18 Years - 60 Years

Date

Study Start Date: 01 Nov 2010
Primary Completion Date: 01 Dec 2011
Study Completion Date: 01 Dec 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria